Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Zheng, Jinping; Baldi, S.; Zhao, Li; Li, Huiping; Lee, Kwan-Ho; Singh, Dave; Papi, Alberto; Grapin, Frédérique; Guasconi, Alessandro; Georges, George

doi:10.1186/s12931-021-01683-2

Cited by 10 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distribution of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades was as follows: grades 3–4, 40,917 (37.9%) patients; grades 2–4, 39,403 (36.5%) patients; and grades 2–3, 27,536 (25.5%) patients. HD-ICS was used in five RCTs 18 – 22 , MD-ICS in 15 RCTs 17 , 23 – 34 , and LD-ICS in 10 RCTs 17 , 23 , 24 , 35 – 39 .…”

Section: Resultsmentioning

confidence: 99%

Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis

Lee

Park

Jang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

A systematic review and Bayesian network meta-analysis is necessary to evaluate the efficacy and safety of triple therapy with different doses of inhaled corticosteroids (ICS) in stable chronic obstructive pulmonary disease (COPD). We selected 26 parallel randomized controlled trials (41,366 patients) comparing triple therapy with ICS/long-acting beta-agonist (LABA), LABA/long-acting muscarinic antagonist (LAMA), and LAMA in patients with stable COPD for ≥ 12 weeks from PubMed, EMBASE, the Cochrane Library, and clinical trial registries (search from inception to June 30, 2022). Triple therapy with high dose (HD)-ICS exhibited a lower risk of total exacerbation in pre-specified subgroups treated for ≥ 48 weeks than that with low dose (LD)-ICS (odds ratio [OR] = 0.66, 95% credible interval [CrI] = 0.52–0.94, low certainty of evidence) or medium dose (MD)-ICS (OR = 0.66, 95% CrI = 0.51–0.94, low certainty of evidence). Triple therapy with HD-ICS exhibited a lower risk of moderate-to-severe exacerbation in pre-specified subgroups with forced expiratory volume in 1 s < 65% (OR = 0.6, 95% CrI = 0.37–0.98, low certainty of evidence) or previous exacerbation history (OR = 0.6, 95% CrI = 0.36–0.999, very low certainty of evidence) than triple therapy with MD-ICS. Triple therapy with HD-ICS may reduce acute exacerbation in patients with COPD treated with other drug classes including triple therapy with LD- or MD-ICS or dual therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis

Lee

Park

Jang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In population-based studies the proportion of current-smoker COPD patients ranged from 34% in Spain to almost 48% in China, with an average of 35.6% [25][26][27][28], whereas in observational studies the proportion ranged from 30% (Daxas in COPD Therapy (DINO) study) to 43.4% (COPDGene cohort) [29][30][31][32][33]. On the other hand, an analysis of individuals with COPD enrolled in some COPD pharmacological clinical trials showed that the proportion of current smokers ranged between 20% and 48%, with an average of 38% [34][35][36][37][38][39][40][41][42][43].…”

Section: Epidemiological Aspects Of Smoking In Copdmentioning

confidence: 99%

Smoking cessation and vaccination

Laucho-Contreras

2023

Eur Respir Rev

View full text Add to dashboard Cite

A significant proportion of COPD patients (∼40%) continue smoking despite knowing that they have the disease. Smokers with COPD exhibit higher levels of nicotine dependence, and have lower self-efficacy and self-esteem, which affects their ability to quit smoking. Treatment should be adapted to the needs of individual patients with different levels of tobacco dependence. The combination of counselling plus pharmacotherapy is the most effective cessation treatment for COPD. In patients with severe COPD, varenicline and bupropion have been shown to have the highest abstinence rates compared with nicotine replacement therapy. There is a lack of evidence to support that smoking cessation reduction or harm reduction strategies have benefits in COPD patients. The long-term efficacy and safety of electronic cigarettes for smoking cessation need to be evaluated in high-risk populations; therefore, it is not possible to recommend their use for smoking cessation in COPD. Future studies with the new generation of nicotine vaccines are necessary to determine their effectiveness in smokers in general and in COPD patients.

show abstract

“…Pharmacologic management of COPD aims for the reduction of the current symptoms and future exacerbation risks [3]. Treatment of the disease is conducted with inhaled bronchodilators, corticosteroids [4], or long-acting beta-agonists.…”

Section: Introductionmentioning

confidence: 99%

“…Treatment of the disease is conducted with inhaled bronchodilators, corticosteroids [4], or long-acting beta-agonists. If the patients have severe symptoms or intense exacerbations, combination therapy has been recommended because it lowers the incidence of exacerbations [3,5]. Budesonide (BUD) belongs to a class of drugs known as corticosteroids.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

β-Cyclodextrin Inclusion Complexes of Budesonide with Enhanced Bioavailability for COPD Treatment

2021

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a life-threatening disease of the respiratory system, affecting many patients worldwide. Budesonide (BUD), a synthetic glucocorticosteroid applied for the treatment of COPD patients, is a hydrophobic compound with low bioavailability. The formation of inclusion complexes of hydrophobic compounds with β-cyclodextrin (CD) through the solvent evaporation technique is an appealing method for the amelioration of the compounds’ in vitro release behavior. In the present study, CD–BUD complexes were prepared through the solvent evaporation technique. The effect of the applied solvent was evaluated through FTIR, scanning electron microscopy (SEM), X-ray diffraction (XRD) analysis, and in vitro release behavior measurements. It was found that the optimum complexes with the minimum degree of crystallinity and the optimum in vitro release behavior are prepared in the solvent ratio H2O/EtOH 80/20 v/v. In a further step, the formation of CD–BUD complexes containing different amounts of BUD was prepared. Through XRD measurements, the degree of crystallinity of the samples was calculated confirming the diminished crystallinity of BUD in CD complexes. The in vitro release of the samples showed the improved release behavior of BUD from the complexes in comparison to neat BUD while a direct correlation between the degree of crystallinity and in vitro release behavior was demonstrated.

show abstract

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Cited by 10 publications

References 19 publications

Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis

Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis

Smoking cessation and vaccination

β-Cyclodextrin Inclusion Complexes of Budesonide with Enhanced Bioavailability for COPD Treatment

Contact Info

Product

Resources

About